Table 1.
Published data on the incidence of post-transplant lymphoproliferative disorder in cardiac transplant recipients.
References | Number of HT recipients | Number of PTLD cases | PTLD incidence | Follow-up time |
---|---|---|---|---|
Couetil et al. (31) | 275 | 2 | 0.7% | NA |
Grattan et al. (32) | 310 | 11 | 3.5% | NA |
Swinnen et al. (33) | 154 | 10 | 6.5% | NA |
Armitage et al. (34) | 439 | 15 | 3.4% | NA |
Rinde-Hoffman et al. (35) | 92 | 5 | 5.5% | NA |
Chen et al. (36) | 424 | 19 | 4.5% | 0.5 years (median) |
Mihalov et al. (37) | 307 | 21 | 6.8% | NA |
Hsu et al. (38) | 156 | 4 | 2.6% | 4.3 years (mean) |
Yagdi et al. (15) | 835 | 30 | 3.6% | 9.6 years (median) |
Crespo-Leiro et al. (14) | 3,393 | 62 | 1.8% | 5.2 years (median) |
Fröhlich et al. (5) | 255 | 18 | 7.0% | 12.6 years (median). |
Higgins et al. (39) | 6,211 | 88 | 1.4% | 5.5 years (median) |
Rivinius et al. (40) | 381 | 11 | 2.9% | 9.7 years (mean) |
Youn et al. (41) | NA | |||
2000–2005 | 8,555 | 83 | 1.0% | |
2006–2011 | 9,032 | 75 | 0.9% | |
Asleh et al. (42) | 523 | 24 | 4.6% (0.6 events per 100 person-years) | 9 years (median) |
HT, heart transplant; PTLD, post-transplant lymphoproliferative disorder.